Fig. 1: IFN-γ induces IFI35 expression in tumor microenvironment.
From: IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion
A Representative immunostainings for IFI35 in TNBC patients’ sample (n = 45). B Histological quantification of IFI35 expression in tumor cells, fibroblasts, immune cells within (A) (one-way ANOVA, Tukeys’s multiple comparison test, mean with SEM is plotted). C Correlation of IFI35 expression in tumor and immune cells (Pearson, n = 45 pairs, two-tailed). D, E RT-qPCR and Immunoblot analysis of BT-549 or MDA-MB-231 with indicated IFN-γ for IFI35 and β-actin as loading control (one-way ANOVA, Tukeys’s multiple comparison test, mean with SEM is plotted).
